Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Heinrich

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|July 31, 2016
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trialFred Saad, Joan Carles, Silke Gillessen, et al.
Hypertension (Dallas, Tex. : 1979)|September 7, 2021
Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial HypertensionFabrizio Buffolo, Jacopo Burrello, Alessio Burrello, et al.
Cancer Immunology Research|February 27, 2019
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number GainAnne Hansen Ree, Vigdis Nygaard, Hege G Russnes, et al.
British Journal of Cancer|January 9, 2025
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE studyJoe M O'Sullivan, Daniel Heinrich, Elena Castro, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
Frontiers in Endocrinology|November 19, 2019
Circulating miRNA Expression Profiling in Primary AldosteronismAbel Decmann, Gábor Nyírö, Ottó Darvasi, et al.
Frontiers in Endocrinology|December 27, 2024
Mild autonomous cortisol secretion leads to reduced volumetric BMD at lumbar spine in patients with primary aldosteronismNabeel Mansour, Denise Bruedgam, Daniel Heinrich, et al.
The Prostate|August 24, 2019
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastasesOliver Sartor, Daniel Heinrich, Neil Mariados, et al.
Frontiers in Endocrinology|September 11, 2023
Integration of clinical parameters and CT-based radiomics improves machine learning assisted subtyping of primary hyperaldosteronismNabeel Mansour, Andreas Mittermeier, Roman Walter, et al.
Vaccines|May 28, 2022
Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2Robert Daniel Heinrich Markewitz, David Juhl, Daniela Pauli, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|July 31, 2016
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trialFred Saad, Joan Carles, Silke Gillessen, et al.
Hypertension (Dallas, Tex. : 1979)|September 7, 2021
Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial HypertensionFabrizio Buffolo, Jacopo Burrello, Alessio Burrello, et al.
Cancer Immunology Research|February 27, 2019
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number GainAnne Hansen Ree, Vigdis Nygaard, Hege G Russnes, et al.
British Journal of Cancer|January 9, 2025
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE studyJoe M O'Sullivan, Daniel Heinrich, Elena Castro, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
Frontiers in Endocrinology|November 19, 2019
Circulating miRNA Expression Profiling in Primary AldosteronismAbel Decmann, Gábor Nyírö, Ottó Darvasi, et al.
Frontiers in Endocrinology|December 27, 2024
Mild autonomous cortisol secretion leads to reduced volumetric BMD at lumbar spine in patients with primary aldosteronismNabeel Mansour, Denise Bruedgam, Daniel Heinrich, et al.
The Prostate|August 24, 2019
Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastasesOliver Sartor, Daniel Heinrich, Neil Mariados, et al.
Frontiers in Endocrinology|September 11, 2023
Integration of clinical parameters and CT-based radiomics improves machine learning assisted subtyping of primary hyperaldosteronismNabeel Mansour, Andreas Mittermeier, Roman Walter, et al.
Vaccines|May 28, 2022
Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2Robert Daniel Heinrich Markewitz, David Juhl, Daniela Pauli, et al.
Pageof 6